Prognostic value of Isocitrate Dehydrogenase And Mismatch Repair Genes In Gliomas | ||
| Zagazig University Medical Journal | ||
| Volume 30, Issue 1.3, March and April 2024, Pages 378-380 PDF (784.59 K) | ||
| Document Type: Review Articles | ||
| DOI: 10.21608/zumj.2023.202612.2777 | ||
| Authors | ||
| Dina Walid Ahmed* 1; Hayam Elsayed Rashed2; Asmaa Hussein Mohamed3; Nelly Mohamed Saeed3; Wael Abdelrahman Elmosalamy4 | ||
| 1Demonstrator of pathology, Faculty of Medicine, Zagazig University, Zagazig, Egypt., medicine, Zagazig, Egypt | ||
| 2Professor of pathology, Faculty of Medicine, Zagazig University, Zagazig, Egypt. | ||
| 3Lecturer of pathology, Faculty of Medicine, Zagazig University, Zagazig, Egypt. | ||
| 4Assistant professor of neurosurgery, Faculty of Medicine, Zagazig University, Zagazig, Egypt. | ||
| Abstract | ||
| Background: Gliomas are considered the most prevalent malignancies of the central nervous system. These tumors are diffusely infiltrative and behave destructively toward the nearby brain tissue. Based on histological grading, gliomas were previously categorized. Histopathology and molecular characteristics are now included in the classification of brain tumors. Glioma prognosis can be predicted, which allows patients to choose an effective course of treatment. It is crucial to look for fresh prognostic indicators in cancer biopsy samples that might indicate prognosis. IDH mutation is a crucial component for the subclass categorization of diffuse gliomas and is just one of many molecular parameters. Significantly, all forms of IDH-mutant gliomas seem to have much better prognosis than malignant diffuse IDH wild type (IDH-wt) gliomas such as glioblastoma. Conclusion: We concluded that IDH1 and MMR genes immunohistochemical expression could help in the prediction of gliomas outcome. More large-scale multicenter investigations are needed to back up our findings. | ||
| Keywords | ||
| Gliomas; Mismatch; Isocitrate; Dehydrogenase | ||
|
Statistics Article View: 123 PDF Download: 93 |
||
